GlobeNewswire Inc.··Sanofi/RegeneronSanofi, Regeneron Win EU Approval for Dupixent in Pediatric Chronic Urticaria
Sanofi and Regeneron win EU approval for Dupixent as first targeted therapy for chronic urticaria in children ages 2-11, expanding the blockbuster drug's market reach.
SNYREGNDupixentdupilumab